Adenovirus is one of the most studied oncolytic viruses in breast cancer, with research mainly in vitro and to a lesser extent in mouse models. It has been observed that the exclusive application of this virus has limited effects in the treatment of breast cancer, so efforts are being made to improve its effectiveness by combining it with other therapeutic agents.
For example, the oncolytic adenovirus SG500 has been genetically modified to express a suicide enzyme that improves its effectiveness when combined with certain chemotherapy prodrugs. Other adenoviruses have been engineered to express angiogenesis inhibitors or growth factors, which have been shown to prolong survival in animal models by limiting tumor growth and metastasis formation.
In combination with placlitaxel, a chemotherapy drug commonly used in breast cancer, the ZD55-IL-24 virus has been shown to increase the induction of apoptosis in cancer cells, with less toxicity than conventional treatment.
Link to original article:
https://ginecologiayobstetricia.org.mx/articulo/virus-en-el-tratamiento-de-cancer-de-mama
However, results in real patients have been mixed, with some trials showing favorable responses but others indicating limited efficacy, especially in patients with triple-negative tumors. Despite this, the potential of oncolytic adenoviruses in the treatment of breast cancer remains the subject of active investigation, with new approaches including genetic modification to improve treatment specificity and efficacy.
In the search for breast cancer medications, breast cancer pills are being investigated. These investigations seek to improve current treatments and offer more effective options for patients with this disease.